5-Amino-4,6-dichloro-2-methylpyrimidine (CAS 39906-04-2; molecular formula C₅H₅Cl₂N₃; molecular weight 177.97 g/mol; IUPAC name 4,6-dichloro-2-methylpyrimidin-5-amine) is supplied as a non-compendial pharmaceutical intermediate under a quality system aligned with ICH Q7 Chapter 12 and ICH Q11. The material appears as a white to off-white crystalline powder with an amino group at C5 and two equivalent chlorine leaving groups at C4 and C6. This substitution pattern permits sequential nucleophilic aromatic substitution (SNAr) at C4 and C6 without participation of the C2 methyl substituent. The product is available in a standard pharma grade for downstream synthesis of oral drug substances and an injectable grade with tightened bioburden, bacterial endotoxin, and subvisible particulate controls. Typical release specifications are orthogonal and include an HPLC area percent assay of not less than 98.0%, total related substances of not more than 1.0%, and individual unspecified impurities of not more than 0.10% when measured with a reversed-phase C18 column and UV detection at 254 nm. Loss on drying per USP 731 is controlled at not more than 0.50%, and residue on ignition per USP 281 is controlled at not more than 0.10%. Residual solvent limits follow ICH Q3C and USP 467; elemental impurities are controlled by the risk-based approach of ICH Q3D using the oral and parenteral permissible daily exposures applicable to the final dosage form.

For dry storage, the product is packaged in double LDPE bags within a fibre drum with desiccant; injectable-grade material receives an additional vacuum-sealed aluminium barrier. The material is dispensed under dry nitrogen or in an area maintained below 30% RH because the C4 and C6 chlorides are hydrolytically labile. Contact with free amines or alkaline aqueous solutions causes premature displacement of chlorine and produces 4,6-diamino or hydroxy derivatives, which are monitored as process impurities. In humid tropical environments, handling time is minimized and the outer packaging is resealed immediately after sampling. Published data for this specific configuration under open tropical humidity is limited; therefore, supplier recommendations restrict bulk transfers to moisture-controlled day tanks or sealed transfer couplings.

What Limits the Shelf-Life Assignment for This Dichloropyrimidine in Humid Climates?

Hydrolysis is the dominant degradation pathway. The C4 and C6 chlorine centres undergo SNAr hydrolysis to 4-hydroxy-6-chloro-2-methylpyrimidin-5-amine and subsequently to 4,6-dihydroxy-2-methylpyrimidin-5-amine. The electron-donating 5-amino group reduces the rate of hydroxide attack relative to the 5-nitro analogue, but the reaction is accelerated above pH 8.0 and at temperatures above 40 °C. Because published kinetic constants for this exact dichloropyrimidine are limited, long-term storage is assigned conservatively using ICH Q1A(R2). A retest period may be supported by data at 25 °C/60% RH and accelerated data at 40 °C/75% RH. The packaging configuration includes desiccant and an aluminium barrier. In process areas, the material is not held in open containers adjacent to water wash bays or basic scrubber drains. The first chlorine displacement occurs more rapidly than the second; the resulting mono-hydroxy intermediate is less reactive but remains a chromatographic marker for moisture ingress. The release specification therefore includes loss on drying and any increase in the mono-hydroxy impurity above the qualified limit triggers a packaging integrity review.

The release specification matrix for the standard and injectable grades is summarized below.

Supplier Control Strategy Under ICH Q11 and ICH Q7

ICH Q7 Chapter 12 requires that purchased starting materials be released before use and that process-related impurities be understood from the synthetic route. The critical quality attributes for this product include identity, assay, related substances, moisture, sulfated ash, residual solvents, and elemental impurities. The synthetic route is controlled from the chlorination of the pyrimidine diol precursor. During scale-up, glass-lined reactors are preferred because chlorination generates hydrogen chloride. pH probe fouling and off-gas scrubber salt deposition have been observed; these operational bottlenecks are managed with regular rinse cycles and scrubber conductivity alarms. The thermal window for the chlorination step is narrow: excess batch temperature accelerates regioisomer formation, while insufficient temperature leaves unreacted starting material. Published data for this specific configuration is limited. Recrystallization solvent selection is controlled to avoid Class 1 solvents; any Class 2 solvents such as dichloromethane are verified by headspace gas chromatography using USP 467 Option B. Batch records capture chlorination temperature, quench pH, and drying vacuum/pressure. Deviation review includes any excursion outside the validated chlorination temperature range. In-process HPLC monitors disappearance of the starting material and formation of the dichloro product.

The analytical method for related substances uses a 150 mm × 4.6 mm, 3.5 µm C18 column maintained at 30 °C; mobile phase A is 25 mM phosphate buffer pH 3.0 and mobile phase B is acetonitrile. The gradient starts at 10% B and rises to 80% B over 30 min. Detection at 254 nm is used for the assay, with a secondary wavelength of 220 nm for early-eluting polar impurities. System suitability requires resolution not less than 2.0 between the mono-hydroxy impurity and the main peak. The retentime of the main peak relative to the reference standard is checked for consistency. Because the product is not a pharmacopoeial monograph, the method is validated according to ICH Q2(R1) for specificity, linearity, accuracy, precision, and robustness. The limit of quantitation for individual impurities is not more than 0.03% relative to the main peak.

Residual solvents are expected from the chlorination and recrystallization steps. A headspace gas chromatographic method with flame ionization detection can resolve dichloromethane, ethanol, and heptane. Class 1 solvents are not used. The limit for dichloromethane, if used, is 600 ppm per ICH Q3C; ethanol and heptane are controlled as Class 3 solvents with loss on drying and total residual solvent verification. Elemental impurities are screened by ICP-MS after microwave digestion. For oral products, the ICH Q3D oral permissible daily exposures for arsenic, cadmium, lead, mercury, cobalt, nickel, and vanadium are applied. For injectable products, the parenteral permissible daily exposures are used instead. The use of glass-lined reactors and stainless-steel transfer lines requires periodic verification of cobalt, nickel, and chromium in the product, but these elements are typically below method detection limits when the process is controlled. Published data for this specific configuration is limited.

The 5-amino substitution differentiates this product from 4,6-dichloro-2-methyl-5-nitropyrimidine. The amino derivative avoids the nitro-reduction step and the associated palladium or platinum residue risk. The nitro analogue is more activated toward SNAr at C4 and C6 because the nitro group withdraws electron density; the amino analogue requires warmer coupling conditions or longer hold times. That lower reactivity reduces premature disubstitution and can improve selectivity in sequential amination. Compared with 2-chloro-5-amino-4,6-dimethylpyrimidine, the 2-methyl product has no C2 leaving group, so coupling chemistry is confined to C4 and C6. Compared with 5-bromo-4,6-dichloro-2-methylpyrimidine, the amino-substituted product can directly form N-linked intermediates without a prior metal-catalyzed amination step. These differences change the impurity profile and residual-metal control strategy of downstream steps.

The material is also distinct from technical-grade 5-amino-4,6-dichloro-2-methylpyrimidine in particle-size distribution and residual solvent burden. Technical-grade material often contains regioisomers from non-selective chlorination and higher levels of the mono-hydroxy derivative. The pharma grade is recrystallized to reduce these impurities and then dried under inert vacuum. In tablet and capsule synthesis routes, a higher-melting or less hygroscopic polymorph may be preferred; however, published data for this specific configuration is limited. The product is supplied as the free base rather than the hydrochloride salt, which avoids chloride counter-ion variation in downstream stoichiometry and reduces total ash content.

When the Material Is Transferred into Sterile Injectable Manufacture

For injectable synthesis, the building block is not sterilized; it enters a downstream synthetic pathway that yields a final API for aseptic processing or terminal sterilization. The injectable-grade is tested for bioburden prior to release and for bacterial endotoxins by compendial methods. If the final injectable product is manufactured by aseptic crystallization and filtration, the 0.22 µm sterilizing filter is placed after the API solution is prepared. The building block is handled in a controlled environment consistent with EU GMP Annex 1 for early intermediates, with final purification in a classified area. Aseptic filling is not performed on the building block; therefore, the building-block specification does not include sterility. Depyrogenation of glassware and contact surfaces at 250 °C for not less than 30 min is applied downstream. For a parenteral final product, the bacterial endotoxin limit is calculated from the maximum clinical dose and route per USP 85. The injectable grade also has a subvisible particulate control strategy; after reconstitution and filtration, the solution is tested per USP 788 using light obscuration and microscopic methods. Any residual moisture in the injectable-grade packaging is controlled to prevent water uptake that would accelerate hydrolysis during warehouse hold. Published data for this specific configuration is limited.

Oral tablet and capsule manufacture uses the final API rather than the building block directly. If this intermediate persists into the final API as a residual impurity, its level is controlled by the final API specification and not by the building-block assay alone. Granulation equipment for the final product—high-shear mixers, fluid-bed dryers, or roller compactors—does not interact with this compound. The relevant handling constraint for the building block is moisture exclusion during storage and batching. For dry granulation of a downstream API containing this pyrimidine ring, the compression parameters are set by the final API's particle size and deformation behaviour, not by this intermediate. For wet granulation, the final API's compatibility with binder solutions is assessed separately; the building block is not included in the granulation matrix as an active component. In capsule filling, the same principle applies: the building block is consumed in upstream chemistry and does not dictate the powder flow or plug formation behaviour of the final formulated product.